Working… Menu

DHA Supplementation and Pregnancy Outcome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00266825
Recruitment Status : Completed
First Posted : December 19, 2005
Results First Posted : February 4, 2016
Last Update Posted : March 14, 2016
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party):
Susan Carlson, PhD, University of Kansas Medical Center

Brief Summary:
The purpose of the study is to determine if increasing DHA intake during pregnancy can increase gestation duration and enhance infant and childhood outcomes related to visual acuity, stereoacuity, attention, and distractibility.

Condition or disease Intervention/treatment Phase
Pregnancy Drug: DHA Other: Placebo capsule Phase 3

Detailed Description:
Although numerous trials show benefits of postnatal DHA supplementation for visual acuity and others show benefits for cognitive function and/or attention, studies of increased DHA exposure during fetal life are needed, especially in the US. Women in the US consume low amounts of DHA compared to other world populations, and this likely means less DHA transfer to the fetus than in many other populations. Prenatal DHA exposure may be more important than postnatal exposure, because animal studies show critical windows for brain DHA accumulation in relation to effects on neurotransmitters such as serotonin, dopamine and GABA.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 350 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Kansas University DHA Outcome Study (KUDOS)
Study Start Date : January 2006
Actual Primary Completion Date : October 2011
Actual Study Completion Date : October 2011

Arm Intervention/treatment
Experimental: DHA capsules
DHA capsules
Drug: DHA
600 mg DHA
Other Name: docosahexaenoic acid

Placebo Comparator: Placebo capsules
Placebo capsule
Other: Placebo capsule
Placebo capsule

Primary Outcome Measures :
  1. Percentage of Total Fatty Acids by Weight [ Time Frame: at time of birth ]
    Measure of RBC-phospholipid-DHA at Birth

  2. Gestational Age [ Time Frame: at time of birth ]
    Gestational age of babies at time of birth in days

  3. Birth Weight [ Time Frame: at time of birth ]
    Weight of baby at birth

  4. Birth Length [ Time Frame: at time of birth ]
    Length of baby at birth

Secondary Outcome Measures :
  1. Ponderal Index [ Time Frame: at time of birth ]
    Ponderal index calculated with formula Weight (g)/length (cm)^3 * 100. It a measure of leanness of a person and is calculated as a relationship between mass and height. Commonly used in pediatrics.

  2. Gender of Babies [ Time Frame: at time of birth ]
  3. Cord RBC-phospholipid-DHA [ Time Frame: at time of birth ]
    Percentage of total fatty acids by weight in cord RBC

  4. Head Circumference [ Time Frame: at time of birth ]
    Measure of circumference of baby's head in centimeters at time of birth.

  5. Preterm Births [ Time Frame: births before week 37 of gestation ]
    Percentage of births occurring at less than 37 weeks of gestation.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years to 36 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Pregnant 8-20 wks at enrollment
  • single fetus
  • BMI <40

Exclusion Criteria:

  • diabetes (Type I, ii, GDM)
  • hypertension (primary, PIH, preeclampsia/eclampsia)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00266825

Layout table for location information
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
United States, Missouri
Truman Medical Center
Kansas City, Missouri, United States, 64108
Sponsors and Collaborators
Susan Carlson, PhD
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Layout table for investigator information
Principal Investigator: Susan E Carlson, PhD University of Kansas Medical Center
Principal Investigator: John Colombo, PhD University of Kansas
Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Susan Carlson, PhD, Professor, University of Kansas Medical Center Identifier: NCT00266825    
Other Study ID Numbers: 10186
R01HD047315 ( U.S. NIH Grant/Contract )
First Posted: December 19, 2005    Key Record Dates
Results First Posted: February 4, 2016
Last Update Posted: March 14, 2016
Last Verified: February 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided